Target intelligence / Profile preview

Hemagglutinin globular head domain (HA globular head domain)

Target
HA globular head domain
Molecular classification
Viral surface glycoprotein domain, Receptor-binding domain, Antigen (viral antigen)
01

Overview

The hemagglutinin globular head domain is the membrane-distal, antigenic region of the influenza hemagglutinin (HA) glycoprotein, composed mainly of HA1 subunit residues. It contains the receptor-binding site (RBS) that recognizes sialic acid residues on host cells, enabling viral attachment and entry. The globular head domain is the primary target for neutralizing antibodies, making it a central focus for influenza vaccine development and immunological studies. High variability in this region (antigenic drift) underlies the necessity for frequent influenza vaccine updates. Structural features include a compact arrangement of α-helices and β-sheets forming a globular domain, with surface loops (130-loop, 150-loop, 190-helix, 220-loop) surrounding the conserved receptor-binding pocket. This domain is a well-validated therapeutic and vaccine target critical to influenza virus infectivity, immunity, and vaccine efficacy.

Other names
HA globular headInfluenza hemagglutinin head domainHA1 globular domainHemagglutinin HA1 head
02

Mechanism of action

Antibodies bind the globular head domain and block virus receptor engagement, preventing viral attachment and entry into host cells. Vaccines elicit antibodies that target the head, neutralizing the virus.

03

Biological functions

Receptor binding (mediates virus attachment to host cell)Antigenicity (major target for neutralizing antibodies)Immune evasion (via antigenic drift/shift)
04

Disease associations

Infection (influenza virus infection)Immune response (major determinant of vaccine efficacy)
05

Safety considerations

Antigenic variation (drift/shift) allows immune escape, decreasing vaccine efficacy and requiring frequent updating of vaccines
06

Interacting drugs

neutralizing monoclonal antibodies (e.g., broadly neutralizing influenza antibodies)

1 more in the full profile.

07

Biomarkers

Hemagglutinin inhibition assay titers against head domain reflect vaccine-induced or natural immunityAntigenic profile of HA head used for viral strain typing and vaccine design

Beyond the preview

Go deeper on Hemagglutinin globular head domain (HA globular head domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin globular head domain (HA globular head domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call